These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 27337298)
1. MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples. McCarthy D; Pulverer W; Weinhaeusel A; Diago OR; Hogan DJ; Ostertag D; Hanna MM Epigenomics; 2016 Jun; 8(6):747-65. PubMed ID: 27337298 [TBL] [Abstract][Full Text] [Related]
2. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
3. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093 [TBL] [Abstract][Full Text] [Related]
4. A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR. Pulverer W; Hofner M; Preusser M; Dirnberger E; Hainfellner JA; Weinhaeusel A Clin Neuropathol; 2014; 33(1):50-60. PubMed ID: 23993306 [TBL] [Abstract][Full Text] [Related]
5. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917 [TBL] [Abstract][Full Text] [Related]
6. Molecular Characteristics of Thalamic Gliomas in Adults. Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Collins VP; Ichimura K; Di Y; Pearson D; Chan R; Thompson LC; Gabe R; Brada M; Stenning SP; Acta Neuropathol Commun; 2014 Jun; 2():68. PubMed ID: 24952577 [TBL] [Abstract][Full Text] [Related]
8. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival. Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998 [TBL] [Abstract][Full Text] [Related]
9. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382 [TBL] [Abstract][Full Text] [Related]
10. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788 [TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275 [TBL] [Abstract][Full Text] [Related]
12. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Preusser M; Elezi L; Hainfellner JA Clin Neuropathol; 2008; 27(6):388-90. PubMed ID: 19130735 [TBL] [Abstract][Full Text] [Related]
13. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224 [TBL] [Abstract][Full Text] [Related]
14. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394 [TBL] [Abstract][Full Text] [Related]
15. Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. Tournier B; Chapusot C; Courcet E; Martin L; Lepage C; Faivre J; Piard F BMC Cancer; 2012 Jan; 12():12. PubMed ID: 22243995 [TBL] [Abstract][Full Text] [Related]
16. Tumor location and patient age predict biological signatures of high-grade gliomas. Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492 [TBL] [Abstract][Full Text] [Related]
17. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069 [TBL] [Abstract][Full Text] [Related]
18. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
19. Detection of IDH1 mutations and the status of MGMT promoter on intraoperative fresh tissue section from frameless neuronavigation needle biopsy. Analysis on 17 patients with brain glial tumor ineligible for craniotomy and tumor resection. Iaccarino I; Nicoli D; Serra S; Froio E; Pisanello A; De Berti G; Ghadirpour R; Marcello N; Servadei F; Carinci F Int J Immunopathol Pharmacol; 2011; 24(2 Suppl):45-50. PubMed ID: 21781445 [TBL] [Abstract][Full Text] [Related]
20. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]